Skip to main content
NewslettersWatchlist

Hemostemix Inc(HEM-X)
TSX Venture

Today's Change
Delayed Last Update

Hemostemix Inc

707 - 7th Avenue SW
Suite 1150
Calgary AB T2P 3H6 CAN
P: 905-580-4170
https://www.hemostemix.com

Sectors & Indices

Sector
Industry
Employees

    Profile

    Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.

    Key Executives

    NameTitle
    Thomas SmeenkCEO/Co-Founder/Director/President
    Fraser C. HendersonChief Medical Officer
    Christina WuCFO
    Peter PavlinVice President, Divisional

    More from The Globe

    ReconAfrica agrees to pay out more than $10-million over allegedly misleading disclosure
    ReconAfrica oil drilling site in Namibia for Geoffrey York and Emma Graney story.
    Dividend investing has lost its mojo. Here’s why – and how to adapt
    Ian McGugan
    The Globe Investing Club 2024: Let the competition begin!
    opinion
    Here’s the real reason your Canadian stocks can’t keep up
    Tim Shufelt
    Dow ends above 40,000 milestone, TSX also at fresh record high
    Traders work on the floor of the New York Stock Exchange (NYSE) on May 16.
    number cruncher
    U.S technology stocks with earnings and price momentum
    For Number Cruncher column in Globe Investor/ROB only.
    Lightspeed Commerce stock soars on better-than-expected profit forecast
    Lightspeed Commerce Inc. CEO Dax Dasilva poses in the company's offices in Montreal, Wednesday, May 8, 2024. THE CANADIAN PRESS/Christinne Muschi
    The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings
    The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

    All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

    Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

    Financial data provided by Zacks Investment Research.